Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Biol Cell ; 35(7): mr5, 2024 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-38809589

RESUMO

Spatial and temporal tracking of fluorescent proteins (FPs) in live cells permits visualization of proteome remodeling in response to extracellular cues. Historically, protein dynamics during trafficking have been visualized using constitutively active FPs fused to proteins of interest. While powerful, such FPs label all cellular pools of a protein, potentially masking the dynamics of select subpopulations. To help study protein subpopulations, bioconjugate tags, including the fluorogen activation proteins (FAPs), were developed. FAPs are comprised of two components: a single-chain antibody (SCA) fused to the protein of interest and a malachite-green (MG) derivative, which fluoresces only when bound to the SCA. Importantly, the MG derivatives can be either cell-permeant or -impermeant, thus permitting isolated detection of SCA-tagged proteins at the cell surface and facilitating quantitative endocytic measures. To expand FAP use in yeast, we optimized the SCA for yeast expression, created FAP-tagging plasmids, and generated FAP-tagged organelle markers. To demonstrate FAP efficacy, we coupled the SCA to the yeast G-protein coupled receptor Ste3. We measured Ste3 endocytic dynamics in response to pheromone and characterized cis- and trans-acting regulators of Ste3. Our work significantly expands FAP technology for varied applications in S. cerevisiae.


Assuntos
Transporte Proteico , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae , Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/metabolismo , Anticorpos de Cadeia Única/metabolismo , Endocitose/fisiologia , Corantes Fluorescentes/metabolismo , Proteínas Luminescentes/metabolismo , Proteínas Luminescentes/genética , Proteínas de Fluorescência Verde/metabolismo , Corantes de Rosanilina
2.
bioRxiv ; 2024 May 23.
Artigo em Inglês | MEDLINE | ID: mdl-38712197

RESUMO

Spatial and temporal tracking of fluorescent proteins in live cells permits visualization of proteome remodeling in response to extracellular cues. Historically, protein dynamics during trafficking have been visualized using constitutively active fluorescent proteins (FPs) fused to proteins of interest. While powerful, such FPs label all cellular pools of a protein, potentially masking the dynamics of select subpopulations. To help study protein subpopulations, bioconjugate tags, including the fluorogen activation proteins (FAPs), were developed. FAPs are comprised of two components: a single-chain antibody (SCA) fused to the protein of interest and a malachite-green (MG) derivative, which fluoresces only when bound to the SCA. Importantly, the MG derivatives can be either cell-permeant or -impermeant, thus permitting isolated detection of SCA-tagged proteins at the cell surface and facilitating quantitative endocytic measures. To expand FAP use in yeast, we optimized the SCA for yeast expression, created FAP-tagging plasmids, and generated FAP-tagged organelle markers. To demonstrate FAP efficacy, we coupled the SCA to the yeast G-protein coupled receptor Ste3. We measured Ste3 endocytic dynamics in response to pheromone and characterized cis- and trans-acting regulators of Ste3. Our work significantly expands FAP technology for varied applications in S. cerevisiae.

3.
J Correct Health Care ; 30(3): 167-171, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38563618

RESUMO

Treatment-resistant schizophrenia (TRS) is a challenging condition to treat for the correctional psychiatrist. Guidelines from the American Psychiatric Association indicate that the first-line pharmacotherapy for TRS is the use of the atypical antipsychotic clozapine. The use of clozapine is unique in that it requires patient adherence with weekly blood draws as a prophylactic measure against agranulocytosis and leukopenia. In the correctional setting, patients with severe and persistent schizophrenia are frequently nonadherent due to lack of insight and anemic access to health care resources, specifically as these pertain to clozapine. Therefore, an alternative treatment option would be a welcome solution for this demographic. Our literature review demonstrates a limited number of studies documenting the successful use of clozapine alternatives or combination antipsychotic therapy for treatment of TRS. In this article, we present a putative case where we believe that a combination regimen of paliperidone palmitate, oral aripiprazole, and escitalopram led to a notable mitigation of both positive and negative symptoms of psychosis in the case of an incarcerated patient with TRS, as well as an improvement in functional stability, which was conducive to housing in a less restrictive setting. A brief review of the published literature follows the report.


Assuntos
Antipsicóticos , Aripiprazol , Esquizofrenia Resistente ao Tratamento , Humanos , Antipsicóticos/uso terapêutico , Antipsicóticos/administração & dosagem , Masculino , Aripiprazol/uso terapêutico , Aripiprazol/administração & dosagem , Esquizofrenia Resistente ao Tratamento/tratamento farmacológico , Adulto , Quimioterapia Combinada , Citalopram/uso terapêutico , Citalopram/administração & dosagem , Palmitato de Paliperidona/administração & dosagem , Palmitato de Paliperidona/uso terapêutico , Esquizofrenia/tratamento farmacológico , Estabelecimentos Correcionais , Clozapina/uso terapêutico , Clozapina/administração & dosagem
4.
Pharmacol Res Perspect ; 11(4): e01115, 2023 08.
Artigo em Inglês | MEDLINE | ID: mdl-37485957

RESUMO

Opioid overdose remains a problem in the United States despite pharmacotherapies, such as buprenorphine, in the treatment of opioid use disorder. This study characterized changes in buprenorphine use. Using the Drug Enforcement Administration's ARCOS, Medicaid, and Medicare claims databases, patterns in buprenorphine usage in the United States from 2018 to 2020 were analyzed by examining percentage changes in total grams distributed and changes in grams per 100 K people in year-to-year usage based on ZIP code and state levels. For ARCOS from 2018 to 2019 and 2019 to 2020, total buprenorphine distribution in grams increased by 16.2% and 12.6%, respectively. South Dakota showed the largest statewide percentage increase in both 2018-2019 (66.1%) and 2019-2020 (36.7%). From 2018 to 2019, the ZIP codes ND-577 (156.4%) and VA-222 (-82.1%) had the largest and smallest percentage changes, respectively. From 2019 to 2020, CA-932 (250.2%) and IL-603 (-36.8%) were the largest and smallest, respectively. In both 2018-2019 and 2019-2020, PA-191 had the second highest increase in grams per 100K while OH-452 was the only ZIP code to remain in the top three largest decreases in grams per 100K in both periods. Among Medicaid patients in 2018, there was a nearly 2000-fold difference in prescriptions per 100k Medicaid enrollees between Kentucky (12 075) and Nebraska (6). Among Medicare enrollees in 2018, family medicine physicians and other primary care providers were the top buprenorphine prescribers. This study not only identified overall increases in buprenorphine availability but also pronounced state-level differences. Such geographic analysis can be used to discern which public policies and regional factors impact buprenorphine access.


Assuntos
Buprenorfina , Transtornos Relacionados ao Uso de Opioides , Idoso , Humanos , Estados Unidos , Buprenorfina/uso terapêutico , Medicaid , Medicare , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Tratamento de Substituição de Opiáceos
5.
Neuroscience ; 442: 114-123, 2020 08 21.
Artigo em Inglês | MEDLINE | ID: mdl-32652174

RESUMO

The timing of voluntary exercise relative to drug conditioning is important to its "neuroprotective" effects, though it is unclear whether the voluntary exercise needs to occur temporally contiguous with drug conditioning, or occur during an early, developmental period, but non-contiguous with drug conditioning, for its "neuroprotective" effects. To distinguish between these two ideas, the timing of voluntary exercise relative to drug conditioning on the development and extinction of conditioned hyperactivity, and induction of sensitization was manipulated in the present experiment. Specifically, half of the exercise mice were permitted access to home-cage running wheels for 6 continuous weeks (Exercise-Exercise) whereas the other half of the exercise mice were permitted access to home-cage running wheels only for the first 3  weeks and then had the wheels removed (Exercise-Sedentary). Likewise, half of the sedentary mice had no home-cage running wheels for 6 continuous weeks (Sedentary-Sedentary) whereas the other half of the sedentary mice were permitted access to the home-cage running wheels for the last 3 weeks prior to the acquisition phase (Sedentary-Exercise). Mice received vehicle or methamphetamine (Meth; 1.0 mg/kg; acquisition), followed by saline-alone sessions (extinction) and finally challenged with an escalating Meth-regimen (0.25 → 1.0 mg/kg). While all Meth-paired groups, regardless of exercise regimen, showed conditioned hyperactivity, Exercise-Exercise and Exercise-Sedentary mice were less responsive to chronic Meth exposure and showed slower extinction compared to the other Meth-paired groups. These results suggest an early exercise regimen, during a critical developmental window, protects against the stimulant properties of Meth and simultaneously facilitates contextual learning.


Assuntos
Estimulantes do Sistema Nervoso Central , Metanfetamina , Preparações Farmacêuticas , Condicionamento Físico Animal , Animais , Estimulantes do Sistema Nervoso Central/farmacologia , Aprendizagem , Metanfetamina/farmacologia , Camundongos
6.
Pharmacol Biochem Behav ; 193: 172934, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32333921

RESUMO

The present experiments determined the effects of voluntary home-cage wheel running on the development (Experiments 1 and 2a) and expression (Experiment 2b) of conditioned hyperactivity and long-term sensitization in male, Swiss-Webster mice. Mice experienced 3 weeks of wheel running (exercise) or not (sedentary) either beginning prior to (Experiments 1 and 2a), or immediately following (Experiment 2b), the acquisition phase. During the acquisition phase, mice (n = 12-15/group) received injections (subcutaneous) of either vehicle (saline) or methamphetamine (0.5 or 1.0 mg/kg, Experiment 1; 1.0 mg/kg, Experiments 2a and 2b) immediately prior to 5 locomotor-activity sessions. The extinction phase began 48 hours (h) (Experiment 1) or 3 weeks (Experiments 2a and 2b) after acquisition and all mice received vehicle injections prior to 4 locomotor-activity sessions. Tests of long-term sensitization occurred 72 h after the last extinction session and involved an escalating, methamphetamine-dose regimen (0.25 âž” 1.0 mg/kg), 1 dose/session for 3 sessions. While pre-acquisition wheel running failed to alter development of conditioned hyperactivity after training with the 0.5 mg/kg methamphetamine dose, it blunted the development of conditioned hyperactivity, and blocked (Experiment 1) or attenuated (Experiment 2a) induction of long-term sensitization after training with the 1.0 mg/kg methamphetamine dose. Furthermore, while post-acquisition wheel running retarded extinction of conditioned hyperactivity, it did not alter expression of conditioned hyperactivity or long-term sensitization (Experiment 2b). Collectively, the results suggest that the impact of voluntary exercise on context-drug associations and long-term sensitization is critically dependent on the timing of exercise relative to drug conditioning.


Assuntos
Condicionamento Psicológico/efeitos dos fármacos , Extinção Psicológica/efeitos dos fármacos , Metanfetamina/administração & dosagem , Metanfetamina/farmacologia , Corrida , Animais , Terapia por Exercício/métodos , Masculino , Camundongos , Modelos Animais , Transtornos Relacionados ao Uso de Substâncias/terapia , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...